Pfizer Licensing Agreement Renewal

Trellus Health plc

("Trellus Health" or the "Company") 

Pfizer Licensing Agreement Renewal

Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programmes and value-based solutions to manage complex chronic conditions, is pleased to announce that it has signed a renewal of its Licensing Agreement with Pfizer Inc. ("Pfizer").

Under the renewed agreement, Pfizer will continue to license Trellus Health's patient support educational content for inclusion within its inflammatory bowel disease ("IBD") digital application. The original agreement was entered into in the second quarter of 2024.

Dr. Marla Dubinsky, CEO and Co-founder of Trellus Health plc said: "We are excited to extend this agreement with Pfizer, which underscores both the continued engagement of their users with our content on the platform and the value of our resilience-driven approach and methodology. Alongside our recent Gastro Health Master Services Agreement, the extension of our collaboration with Johnson & Johnson, and the continued roll-out of TrialSet™ across clinical trials, this renewal further supports the applicability of our platform across the pharmaceutical lifecycle. We remain focused on advancing commercial discussions and converting pipeline opportunities into revenue."

As previously announced, the Company has reduced its monthly cash burn to an average of c. $300k as of March 2026. With this renewal, as well as a loan from Laurie Keefer, Ph.D.,the Company's scientific co-founder and co-inventor of the Company's resilience methodology, the Company expects its cash runway to extend into May 2026.

The Board remains supportive of the Company's commercial strategy and is engaged in ongoing discussions regarding a range of potential funding options to further extend the Company's cash runway.

Enquiries:

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health® integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health® considers its approach to have potential utility and demand across many conditions.

The Company also offers Trellus TrialSet™, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement

The Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com